 |
|
|
| |
Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase 3 Study
|
| |
| |
CROI February 22-25, 2026; Denver, CO, USA.
Chloe Orkin, MD1; Rosie Mngqibisa, MD2; Juan Diego Velez, MD3; Princy Kumar, MD4; Dominique Braun, MD5; Andrew Carr, DSc6; Mark Bloch, MD7; Sharon Walmsley, MD8; Pablo Tebas, MD9; Alexandra Calmy, MD10; Monica Fuszard, MS11; Tracy Diamond, PhD11; Beth Jackson, BS11; Michelle C. Fox, MD11; Jason Kim, MD, MSCE11
1Queen Mary University of London, London, UK; 2Enhancing Care Foundation, Wentworth Hospital, Durban, South Africa; 3Fundación Valle del Lili,
Cali, Colombia; 4Division of Infectious Diseases, Georgetown University Medical Center, Washington DC, USA; 5University Hospital, Zurich, Switzerland; 6University of New South Wales, Sydney, Australia; 7Holdsworth House, Sydney, Australia; 8University of Toronto Department of Medicine, Ontario, Canada; 9Penn Center for AIDS Research, University of Pennsylvania, Philadelphia, PA, USA; 10HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; 11Merck & Co., Inc., Rahway, NJ, USA
|
| |
|
|
|
|
|
